While InterMune (NASDAQ:ITMN) was technically a loser today after falling 3%, this can only be seen as natural profit-taking after the stock detonated upward 170% in a single day earlier this week. The company has a first-in-class idiopathic pulmonary fibrosis drug that just aced its phase 3 trial and has solid market potential, possibly up to half a billion dollars in annual sales.
This being InterMune's only drug, Motley Fool health-care analyst David Williamson says in the following video that he agrees with analysts that this now looks like a takeover target. In the video, David looks ahead to the FDA approval process and discusses InterMune's chances of a favorable ruling, and discusses which companies would make the most likely suitors. This will definitely be a story to watch this year.
Biotech stocks can be risky, but they can also make you rich
The best way to play the biotech space is to find companies that shun the status quo and instead discover revolutionary, groundbreaking technologies. In The Motley Fool's brand-new free report "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about a new technology that Big Pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.
David Williamson has no position in any stocks mentioned. The Motley Fool recommends Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.